17,261 trials
Carcinoma, Hepatocellular
Primary: Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS) — 19.0; 21.5; 24.2; 17.9 Months
Age-Related Macular Degeneration
Primary: Phase I: Percentage of Participants With Adverse Events — 11; 10; 10 Participants — p=1.00
Glioblastoma · Glioblastoma Multiforme · Gliosarcoma
Primary: Phase 1- Determination of the Maximum Tolerated Dose (MTD) of Enzastaurin — 250 milligrams (mg)
Acute Pancreatitis · Intra-abdominal Hypertension
Primary: Percent Change of IAP After Treatment — -18.7; -5.4; -27.2; -20.0 percent change of IAP
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 11.1 Months
Avian Influenza · Influenza · Influenza Immunisation
Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Against the 2017 H7N9 Inactivated Influenza Vaccine (IIV) Strain After Second H7N9…
Lymphoma, Large Cell, Diffuse
Primary: Percent of Participants With Progression Free Survival (PFS) After 1 Year Treatment — 16.4 percentage of participants
Pain
Primary: Change in Patient-reported Worst Pain Between Baseline and 5 Weeks of Treatment With Duloxetine — 6.54; 0.25; 4.06 score on a scale
Human Immunodeficiency Virus
Primary: Number of Participants With Severe and Life-threatening Adverse Events (AEs) — 0; 4; 4; 0 Participants
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) — 0.043; 0.016 Liters — p=0.7374
Colonic Neoplasms
Primary: Percentage of Participants With Progression Free Survival (PFS) at 6 Months — 27.50 percentage of participants
Autoantibody Positive · Non-diabetic Relatives at Risk for Type 1 Diabetes · High Risk
Primary: Rate of New Diabetes Per Year — 43; 72 N diabetes per 100 participant years
Hypercholesterolemia · Heterozygous Familial Hypercholesterolemia
Primary: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death — 12; 42; 54; 4 Participants
Healthy Volunteers Diabetes Mellitus, Type 2 · Healthy Volunteers Overweight · Healthy Volunteers Obesity
Primary: Intensity of Injection Site Pain — 35.1; 4.4 score on a scale — p=<0.0001
Multiple Sclerosis · Fatigue
Primary: Change in Daily Fatigue Severity Score — -0.05; -0.05 score on a scale